Estimation of SARS-CoV-2 emissions from non-symptomatic cases

A.A.Prof. Dr. Michael Riediker[1], Dr. Dai-Hua Tsai[1,2]

1 Swiss Centre for Occupational and Environmental Health, Winterthur, Switzerland

2 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland

Key Points

Question: How much SARS-CoV-2 virus is released from a case by breathing and coughing, and what is the resulting concentration in a room?

Finding: Both, breathing and coughing are predicted to release large numbers of viruses, which can lead to billions of virus copies/m^3 in a poorly ventilated room with a coughing emitter.

Meaning: These results may explain the high rate of transmissions and implies the need for strict respiratory protection when people are in the same room with a COVID-19 case.

Word counts:

Abstract: 272, Manuscript: 1801, Tables: 1, Figures: 3

Address for correspondence

Michael Riediker

michael.riediker@alumni.ethz.ch

Swiss Centre for Occupational and Environmental Health (SCOEH)

Binzhofstrasse 87, CH-8404 Winterthur, Switzerland

Abstract

Importance: Cases of the coronavirus disease 2019 (COVID-19) with no or mild symptoms were reported to frequently transmit the disease even without direct contact. The severe acute respiratory syndrome virus (SARS-COV-2) was found at very high concentrations in swab and sputum of such cases.

Objective: We aimed to estimate virus release from such cases into different aerosol sizes by normal breathing and coughing, and what exposure can result from this in a room shared with such as case.

Data Sources and Model: We combined the size-distribution of exhaled breath aerosols for coughing and normal breathing with viral sputum concentrations as approximation for lung lining liquid to obtain an estimate of emitted virus levels. The resulting emission data fed a single-compartment model of airborne concentrations in a room of 50m^3, the size of a small office or medical exam room.

Results: The estimated viral load in aerosols emitted by patients while breathing normally was on average 0.34 copies/cm^3 and could go up to 11.5 copies/cm^3. The corresponding numbers for coughing patients were 10,900 copies/cm^3 and 366,000 copies/cm^3, respectively, per cough. The resulting concentrations in a room with a coughing emitter were always very high, up to 2.02*10^9 copies/m^3. However, also regular breathing aerosol from high emitters was predicted to lead to several thousand copies/m^3.

Conclusions and Relevance: These very high predicted virus concentrations may provide an explanation why for COVID-19, frequent community transmissions from non-symptomatic cases and also high infection rates in medical staff in hospital settings were reported. Our findings suggest that strict respiratory protection is needed when there is a chance to be in

the same room with a patient - whether symptomatic or not - especially if this was for a prolonged time.

Introduction

The novel Coronavirus disease 2019 (COVID-19), emerged in late 2019 in Wuhan, China [1] from where it spread to the entire world. COVID-19 is caused by a novel type of Coronavirus, the severe acute respiratory syndrome virus (SARS-COV-2) [2]. The host-receptor for SARS-CoV-2 was found to be Angiotensin I converting enzyme 2 (ACE2), which is present in cells of the lungs and airways [3]. A large number of patients hospitalized for other reasons and also an important proportion of the medical staff contracted COVID-19 [4]. This is remarkable given that medical professionals are trained at protecting themselves against infections. Also a series of community-transmissions were reported from cases that had no apparent symptoms, some even without direct contact [5–8]. Correspondences about the viral load in samples from COVID-19 patients having no or only mild symptoms reported very high concentrations of SARS-CoV-2 in swab samples [8–10]. This raised the question whether transfections could occur via the air.

When coughing, humans release thousands of aerosol droplets per cubic-centimeter in the size range of 0.6 to 15 µm, with the droplet concentration increasing strongly with cough flow rate [11]. But also normal breathing will lead to some aerosol production, which is attributed to fluid film rupture in the respiratory bronchioles during inhalation leading to the formation of droplets that are released during exhalation [12]. The size of these droplets is mostly below 1 µm [13]. The mode of droplet generation implies that they consist of lung lining liquid including dispersed viruses. Indeed, human volunteers exposed to virus-sized nanoparticles show nano-scaled particles in their exhaled breath [14,15]. Also, the described

size distribution of particles emitted from coughing as well as normal respiration suggests that an important proportion of them will be able to remain airborne for many hours in turbulent conditions [16].

Objectives

This study aimed to estimate the cumulative viral load released from COVID-19 patients with no to moderate symptoms in different aerosol sizes via respiration and coughing. We then used this information to make a risk appraisal for the situation of a high emitter that is either breathing normally or coughing in a room operated at different air exchange rates. We chose a room size that is similar to a medical examination room or an office shared by two to three people.

Design and Methods

Concept:

The release of viruses from individual patients was modeled by first calculating the viral load per exhaled droplets formed during normal breathing and while coughing. The resulting size-distribution provided an initial estimate of the concentration of SARS-CoV-2 virus copies released by a regularly breathing or coughing patient. This viral emission factor was then fed into a well-mixed one-compartment model to simulate the situation in a closed room with different ventilation air exchange rates.

Data sources:

Data on the number of viral copies present in sputum was used to estimate the SARS-CoV-2 viral load present in the lining liquid of respiratory bronchioles in patients [9], specifically an average of 7*10^6 copies/ml with a maximum of 2.35*10^9 copies/ml (hereafter referred to

as "high emitters"), and 1,000 copies/ml representing a low-virus producing patient ("low emitters").

Exhaled aerosol size distributions and numbers were retrieved from published studies on coughing [11] and healthy persons [12]. Both studies assessed the size-number distribution of freshly emitted aerosols. The concentration of viral copies in each aerosol size was calculated from the volume of the aerosols, the actual count number in each size and the above-mentioned virus-load per ml sputum. The viral load in the actual aerosol counts in each aerosol size was then used to calculate the total viral concentration. The cumulative emissions in the PM_{10} fraction were summed up after applying the standard size fractionation curves [17] to the aerosol distribution.

Model:

A one-compartment model estimated the virus load concentration C for a perfectly mixed room of volume V_R of 50 m^3 with one patient as source, using the following mass-balance (equation 1):

$$V_R * \frac{dC}{dt} = c_{PM10} * RR * V_t - \frac{V_R}{ER} * C(t) - \frac{ln(2) * V_R}{t_{½}} * C(t) \quad (1)$$

The emission rate was calculated from the concentration c_{PM10}, the viral load in the PM_{10}-size range, which are particles collected with a 50% efficiency cut-off at 10 µm aerodynamic diameter; and a respiratory rate of 15 breaths per minute (RR) at a tidal volume of V_t of 500 ml per breath. Air exchange rates (ER) used were 1-, 3-, 10- and 20-times per hour. The virus' half-life $t_{½}$ of 1.1 hours was obtained from an experimental study about the persistence of SARS-CoV-2 on surfaces and when airborne [18], tested by assessing the 50% tissue culture infective dose ($TCID_{50}$).

111 The model for coughing was identical, except that coughing was assumed to happen every
112 30 seconds at a volume of 250 ml.

113 All statistics and models were calculated using Stata/SE 15.1 (Mac 64-bit Intel, Rev. 03 Feb
114 2020, StataCorp, College Station, TX, USA).

115 Results

116 Emissions from normal breathing patients

117 To estimate the virus emissions from patients breathing normally, we first calculated the
118 viral load for the aerosol size distribution. Figure 1 shows that the highest virus load is
119 present in the largest aerosol size. The cumulative total emission per breath was 0.34
120 copies/cm^3(air) for an average patient, and 11.5 copies/cm^3 for high emitters. The
121 cumulative emissions in the PM_{10} fraction were about 1/3 of these values with 0.12
122 copies/cm^3 (average) and 4.1 copies/cm^3 (high) per breath.

123 Emission from coughing patient

124 We then estimated the virus emissions from a coughing patient (Figure 2). The cumulative
125 total emission per cough was 19,400 copies/cm^3 for an average patient, and 651,315
126 copies/cm^3 for high emitters. The cumulative emissions in the PM_{10} fraction were about 1/2
127 of these values with 10,900 copies/cm^3 (average) and 366,000 copies/cm^3 (high) per cough.

128 Exposure estimation for bystanders

129 To estimate the exposure of bystanders spending time in the same room as a COVID-19
130 positive person, we calculated the time-course of the viral load in the thoracic size fraction
131 for aerosols released from a high-emitter either breathing normally or coughing. Figure 3
132 shows the results for a high-emitting patient coughing frequently.

For a typical hospital ventilation situation of 10 air exchanges per hour, the concentration plateaus after about 30 minutes, while for a typical office with 3 air exchanges/hour, concentrations continue to rise for almost three hours. In the used model, concentrations scale linearly with the patient emission rate, the plateau concentrations for different emitting patients and ventilation types are summarized in Table 1.

Discussion

An elevated number of viruses is expected to be released by COIVD-19 patients in the form of airborne aerosols, especially when they are coughing. While the bigger portion of the emitted viral load is in the form of large particles that can deposit rapidly, there is also an important portion in the smaller size fractions. Small aerosols can remain airborne for an extended time [16] and are very effective at reaching the deeper regions of the lungs.

An average person breathes about a half m^3 per hour in resting state [19], which can rapidly increase to several m^3 during exercise [20]. Thus, a person spending time in a room with an average emitting patient breathing normally has a realistic chance of inhaling tens to hundreds of copies of the virus even when keeping distance from that person. The situation is worse in the presence of a high emitter and worst if the patient is a coughing high emitter. A review of a wide range of respiratory viruses suggests that the infective dose is often quite low. Sometimes as few as few hundred units of active virus ($TCID_{50}$) [21] seem sufficient to provoke a disease. Thus, our modelling suggests that there is a clear risk of infections for a person spending an extended time in the room with an infected person, even if the distance is too large for direct transmission. The situation is worse if the person is coughing.

The very high virus load in exhaled respiratory aerosols proposed by our assessment may be an explanation why COVID-19 was associated with much more transfections to hospital staff

156 than what was expected from SARS [4]. While having everybody wear a surgical face mask can
157 be an effective source control [22], the protective factors may still be insufficient if an
158 extended amount of time is spent in the same room, especially if the room is small and the
159 ventilation low. Increasing ventilation can help to some extent but is not sufficient in a room
160 of the size of a typical office or medical exam room. Note also that ventilation design for
161 hospitals is complex and not always functioning as intended [23].

162 What are the implications for the normal life and the workplace?

163 - The risk of infection is real when being near an infected person in a room for more
164 than a few minutes and this even when keeping distance to that person.
165 - Sharing a workplace in a small room with a non-symptomatic case seems not
166 advised. This implies that workplaces should not be shared as long as there are no
167 rapid tests to differentiate between healthy and non-symptomatic cases.
168 - Medical staff is advised to wear the best possible respiratory protection whenever in
169 the same room as a patient, especially when this person is coughing.
170 - In addition, every patient, also non-symptomatic ones, should wear a well-fitting
171 surgical face mask to reduce emissions, which will increase the overall protection for
172 the medical staff.

173 Our assessment has a number of limitations. Namely:

174 - The estimated virus levels strongly depend on the number of virus copies produced
175 by a COVID-19 case. We used sputum data from a well described peer-reviewed
176 study [9] assuming that it is a reasonable approximation for the virus load in the
177 respiratory bronchioles, the space where most respiratory aerosols are formed. Our

178 high-emitter estimates would be 100-fold higher if the most extreme
179 correspondence data was used [10].

- 180 We used information about virus copies but compare the results with $TCID_{50}$ infective
181 dose. Research on other virus types suggests that the number of virus copies and
182 $TCID_{50}$ are comparable [24]. However, it would be important to confirm this
183 relationship for the case of SARS-CoV-2.
- 184 For breath aerosols release, we used data reported for normal breathing young
185 healthy subjects. However, aerosol formation is influenced by surface tension of the
186 lung lining liquid [25]. It is likely that aerosol formation will be altered in COVID-19
187 positive cases but it is not clear in which direction.
- 188 Aerosol droplet will shrink in dry air [26], resulting in a shift to smaller particle sizes.
189 This will not directly change the number of copies in the PM_{10} range but simply
190 upconcentrate the viral load per aerosol. While we addressed passivation of viruses
191 in the air by using the documented half-life [18], it is still possible that viruses in smaller
192 droplets are quicker passivated because of shorter diffusion distances for airborne
193 oxidants and faster increasing salinity. Our estimates would be slightly smaller if this
194 was relevant.

195 Acknowledgments

196 This modelling was entirely funded by the Swiss Centre for Occupational and Environmental
197 Health (SCOEH).

198 ## References

199 • 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
200 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.
201 doi:10.1056/NEJMoa2001017

202 • 2. Gorbalenya AE, Baker SC, Baric RS, et al. *Severe Acute Respiratory Syndrome-*
203 *Related Coronavirus: The Species and Its Viruses – a Statement of the Coronavirus Study*
204 *Group*. Microbiology; 2020. doi:10.1101/2020.02.07.937862

205 • 3. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues
206 identify cell types and receptors of human coronaviruses. *Biochem Biophys Res*
207 *Commun*. March 2020:S0006291X20305234. doi:10.1016/j.bbrc.2020.03.044

208 • 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients
209 With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*.
210 2020;323(11):1061. doi:10.1001/jama.2020.1585

211 • 5. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of
212 COVID-19. *JAMA*. February 2020. doi:10.1001/jama.2020.2565

213 • 6. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic
214 SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King
215 County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(13):377-
216 381. doi:10.15585/mmwr.mm6913e1

217 • 7. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the
218 rapid dissemination of novel coronavirus (SARS-CoV2). *Science*. March 2020.
219 doi:10.1126/science.abb3221

220 • 8. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory
221 Specimens of Infected Patients. *N Engl J Med*. 2020;382(12):1177-1179.
222 doi:10.1056/NEJMc2001737

223 • 9. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of
224 hospitalized patients with COVID-2019. *Nature*. April 2020. doi:10.1038/s41586-020-
225 2196-x

226 • 10. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical
227 samples. *Lancet Infect Dis*. 2020;20(4):411-412. doi:10.1016/S1473-3099(20)30113-4

228 • 11. Yang S, Lee GWM, Chen C-M, Wu C-C, Yu K-P. The Size and Concentration of
229 Droplets Generated by Coughing in Human Subjects. *J Aerosol Med*. 2007;20(4):484-
230 494. doi:10.1089/jam.2007.0610

231 • 12. Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. *J*
232 *Aerosol Med Pulm Drug Deliv*. 2009;22(3):229-237. doi:10.1089/jamp.2008.0720

233 • 13. Papineni RS, Rosenthal FS. The Size Distribution of Droplets in the Exhaled
234 Breath of Healthy Human Subjects. *J Aerosol Med*. 1997;10(2):105-116.
235 doi:10.1089/jam.1997.10.105

236 • 14. Gschwind S, Graczyk H, Günther D, Riediker M. A method for the preservation
237 and determination of welding fume nanoparticles in exhaled breath condensate. *Env*
238 *Sci Nano*. 2016;3(2):357–364. doi:10.1039/C5EN00240K

239 • 15. Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath
240 condensate as a matrix for combustion-based nanoparticle exposure and health effect
241 evaluation. *J Aerosol Med Pulm Drug Deliv*. 2014;27(6):449–458.
242 doi:10.1089/jamp.2013.1101

243 • 16. Willeke K, Baron PA, eds. *Aerosol Measurement: Principles, Techniques, and*
244 *Applications*. New York: Van Nostrand Reinhold; 1993.

245 • 17. BSI. *EN 481:1993 Workplace Atmospheres. Size Fraction Definitions for*
246 *Measurement of Airborne Particles*. BSI; 1993.

247 • 18. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability
248 of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*. March
249 2020:NEJMc2004973. doi:10.1056/NEJMc2004973

250 • 19. Beardsell I, ed. *Get through MCEM. Part A: MCQs*. London: RSM; 2011.

251 • 20. Ramos CA, Reis JF, Almeida T, Alves F, Wolterbeek HT, Almeida SM. Estimating
252 the inhaled dose of pollutants during indoor physical activity. *Sci Total Environ*.
253 2015;527-528:111-118. doi:10.1016/j.scitotenv.2015.04.120

254 • 21. Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory
255 and Enteric Viruses Transmitted Through Food and the Environment. *Food Environ*
256 *Virol*. 2011;3(1):1-30. doi:10.1007/s12560-011-9056-7

257 • 22. Patel RB, Skaria SD, Mansour MM, Smaldone GC. Respiratory source control
258 using a surgical mask: An *in vitro* study. *J Occup Environ Hyg*. 2016;13(7):569-576.
259 doi:10.1080/15459624.2015.1043050

260 • 23. Grosskopf KR, Herstein KR. The aerodynamic behavior of respiratory aerosols
261 within a general patient room. 2012;18(4):15.

262 • 24. Kim J-O, Kim W-S, Kim S-W, et al. Development and Application of
263 Quantitative Detection Method for Viral Hemorrhagic Septicemia Virus (VHSV)
264 Genogroup IVa. *Viruses*. 2014;6(5):2204-2213. doi:10.3390/v6052204

265 • 25. Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols.
266 *Proc Natl Acad Sci*. 2004;101(50):17383-17388. doi:10.1073/pnas.0408159101

267 • 26. Holmgren H, Bake B, Olin A-C, Ljungström E. Relation Between Humidity and
268 Size of Exhaled Particles. *J Aerosol Med Pulm Drug Deliv*. 2011;24(5):253-260.
269 doi:10.1089/jamp.2011.0880

270

271 ## Figure legends

272 Figure 1: Size distribution of exhaled aerosols (left) during normal respiration and resulting
273 viral emissions per breath (right) for average (red), high and low emitters (spike-lines) per
274 aerosol size.
275 Figure 2: Size distribution of exhaled aerosols (left) during coughing and resulting viral
276 emissions per breath (right) with average (red), high and low emitters (spike-lines) per
277 aerosol size.

Figure 3: Temporal course of airborne virus load in a perfectly mixed room of 50 m3 for different air exchange rates. The emitter has a high virus-load in the lungs and is coughing intermittently.

Tables

Table 1: Plateau concentration for different combinations of air exchange rate, emission form and emitter type.

Air exchange rate (times/ hour)	1 / hour	3 / hour	10 / hour	20 / hour
Time until 99% of plateau	169 minutes	77 minutes	26 minutes	14 minutes
	Airborne viral concentration at plateau (copies/m^3)			
Regular breathing				
Low emitter	0.0096	0.0043	0.0015	0.0008
Average emitter	44.80	20.18	6.87	3.54
High emitter	22,554	10,100	3,458	1,782
Frequent coughing				
Low emitter	859	386	132	67.9
Average emitter	4,010,000	1,800,000	615,000	317,000
High emitter	2.02e+09	9.06e+08	3.10e+08	1.60e+08

Figure 1


Aerosol droplets per breath [dN/dlogD$_p$/cm^3]
1.5
1
.5
0
.5
1
2
5
10
20
Aerosol size [μm]
Virus load in exhaled breath [dN/dlogD$_p$ /cm^3]
1.0e+02
1.0e+00
1.0e-02
1.0e-04
1.0e-06
.5
1
2
5
10
20
Aerosol size [μm]

Figure 2


6000
4000
2000
0
Aerosol droplets per cough [dN/dlogD$_p$/cm^3]
.5
1
2
5
10
20
Aerosol size [μm]
1.0e+06
1.0e+04
1.0e+02
1.0e+00
1.0e-02
Virus load in exhaled cough [dN/dlogD$_p$ /cm^3]
.5
1
2
5
10
20
Aerosol size [μm]

Figure 3


1/hour
3/hour
10/hour
20/hour
Airborne virus load for high emitter cough [copies/m³ in PM₁₀]
2,500,000,000
2,000,000,000
1,500,000,000
1,000,000,000
500,000,000
0
0
20
40
60
80
100
120
140
160
180
Minutes